Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Table. 1.

Autophagy inducers for improving cancer

Compound Target or mode of action Cancer types References
Rapamycin mTOR MCF-7 Breast Cancer, B16 melanoma, Panic-1 pancreatic carcinoma Busca et al., 1996; Grewe et al., 1999; Chang et al., 2007
Everolimus mTOR Lymphoblastic B cells Neri et al., 2014
Temsirolimus (CCI-779) mTOR Adenoid cystic carcinoma Liu et al., 2014
Metformin AMPK Prostate cancer cells, myeloma Sesen et al., 2015; Wang et al., 2018; Mishra and Dingli, 2019
Perifosine Akt Multiple myeloma, neuroblastoma, colorectal cancer, neuroblastoma cells Li et al., 2010, 2011; Richardson et al., 2012
Ibrutinib Bruton's Tyrosine Kinase (BTK) Skin cancer cell lines, HS-4 and A431 Sun et al., 2018
Suberoylanilidehydroxamic acid (SAHA) Histone deacetylase (HDAC), mTOR Cutaneous T cell lymphoma, glioblastoma stem cells Gammoh et al., 2012; Chiao et al., 2013
Magnolin LIF/Stat-3/Mcl-1 Colorectal cancer cells Yu et al., 2018
Resveratrol SIRT1 Prostate cancer cells, MCF-7 cells El-Mowafy and Alkhalaf, 2003; Li et al., 2014
Spermidine AMPK Colon cancer cells Morselli et al., 2011
Biomolecules & Therapeutics 2020;28:503~511 https://doi.org/10.4062/biomolther.2020.155
© Biomolecules & Therapeutics